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Edited by Noboru MizushimaAbstract In this work we present evidence that A769662, a no-
vel activator of AMP-activated protein kinase (AMPK), is able
to inhibit the function of the 26S proteasome by an AMPK-inde-
pendent mechanism. Contrary to the mechanism of action of
most proteasome inhibitors, A769662 does not aﬀect the proteo-
lytic activities of the 20S core subunit, deﬁning in this way a no-
vel mechanism of inhibition of 26S proteasome activity.
Inhibition of proteasome activity by A769662 is reversible and
leads to an arrest of cell cycle progression. These side eﬀects
of this new activator of AMPK should be taken into account
when this compound is used as an alternative activator of the ki-
nase.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Protein degradation1. Introduction
Proteasomes are one of the major pathways of intracellular
protein degradation in mammalian cells [1–4]. Although
proteasomes can degrade proteins by ubiquitin-independent
processes, they are mostly involved in the ATP- and ubiqui-
tin-dependent pathway of protein degradation [5]. The 26S
proteasome itself is also an ATP-dependent complex. This
complex consists of the 20S catalytic core, where the proteins
are degraded, plus one or two 19S regulatory complexes. The
19S complex is composed of at least 19 diﬀerent subunits that
form a lid- and a base-like structure; the lid provides the bind-
ing sites for poly-ubiquitinated substrates and a deubiquitinat-
ing activity involved in recycling of ubiquitin moieties upon
substrate degradation; the base includes six ATPases that
interact with the 20S proteolytic core; these ATPases have
chaperone function and are required for the unfolding of sub-
strates and their translocation to the 20S proteolytic chamber
[6–8]. Therefore, intracellular protein degradation by the*Corresponding author. Address: Instituto de Biomedicina de
Valencia, CSIC, Jaime Roig 11, 46010-Valencia, Spain.
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doi:10.1016/j.febslet.2008.06.044proteasome is a highly energy-demanding process and, thus,
it is expected that under conditions of energy depletion this
process should be tightly regulated.
AMP-activated protein kinase (AMPK) is a conserved sen-
sor of cellular energy. AMPK is a heterotrimer composed of
three diﬀerent subunits, i.e. a, b and c. AMPKa is the catalytic
subunit, whereas AMPKb and AMPKc play regulatory roles
(see [9], for review). Activity of AMPK complex is regulated
by the phosphorylation of the catalytic a-subunit at Thr172
by an upstream kinase, sharing LKB1 and CaMKKb this role
(see [9], for review). The activated kinase switches on ATP-
generating catabolic pathways while turning oﬀ many ATP-
requiring processes. Since AMPK is a sensor of cellular energy,
it seems plausible that AMPK plays a role in the regulation of
proteasomal protein degradation. In fact, we have recently de-
scribed that AMPK activation (produced by AICAR or met-
formin) results in an inhibition of proteasomal activity [10].
Since AICAR has side eﬀects in cell metabolism that are not
related to AMPK activation, we decided to conﬁrm our results
by the use of the A769662 compound, a novel activator of
AMPK [11–13].
In this work we describe that A769662 is an inhibitor of pro-
teasomal function that acts by an AMPK-independent mecha-
nism. Inhibition of proteasome activity by A769662 is
reversible and leads to an arrest of cell cycle progression. To
our knowledge, this is the ﬁrst time that side eﬀects of this
compound are described and they should be taken into ac-
count when this compound is used as an alternative activator
of AMPK.2. Materials and methods
2.1. Materials
A769662 was kindly provided by Dr. Kei Sakamoto (MRC Protein
Phosphorylation Unit, College of Life Sciences, University of Dundee)
and dissolved in DMSO. Lactacystin and epoxomicin were from Bio-
mol Research Labs (Exeter, UK). AMPKa subunit double knockout
mouse embryonic ﬁbroblasts (MEFs) (a1/ and a2/) and wild-
type controls were grown as described previously [14]. HEK-GFPu-1
cells [15] were from the American Type Culture Collection.
2.2. In vivo determination of proteasome activity
Wild-type and AMPKa subunit double knockout (a1/ and
a2/) MEFs (35000 cells) were grown in complete DMEM medium
(Lonza Bioscience, Barcelona). Then, they were incubated for 1 h inblished by Elsevier B.V. All rights reserved.
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diﬀerent amounts of A769662 (from 10 to 300 lM) or the correspond-
ing vehicle (DMSO). Finally, the chymotrypsin-like activity of the
26S proteasome was measured using the Proteasome-Glo Cell-
Based Assay with N-Suc-LLVY-aminoluciferin as substrate (Promega,
Madison, WI), following the manufacturers instructions. Luminis-
cence was measured in a Spectra Max M5 microplate reader (Molecu-
lar Devices, Sunnyvale, CA). Results were referred to the activity
found in wild-type MEFs cells growing in KH medium with
DMSO.
HEK-GFPu-1 cells were cultured in DMEM medium and then incu-
bated for 1 h in KH medium containing lactacystin (10 lM), diﬀerent
amounts of A769662 (50 lM or 300 lM) or the corresponding vehicle
(DMSO). Fluorescence was determined by ﬂow cytometry using a
FACScanto ﬂow cytometer (Becton Dickinson) using an excitation la-
ser at 488 nm and GFP ﬂuorescence detection at 520 nm.2.3. In vitro determination of proteasome activity
To measure the in vitro activity of the 26S proteasome we used a
commercial 26S proteasome preparation (from human erythrocytes,
Biomol Research Labs, Exeter, UK) combined with a ﬂuorescent
detection procedure (based on the degradation of FITC-casein) from
Sigma (St. Louis, Mo), as described in [16]. The in vitro activity of
the 20S proteasome was measured using the commercial 20S Protea-
some Assay Kit from Biomol Research Labs (Exeter, UK) containing
a puriﬁed preparation of the 20S proteasome from human erythrocytes
and Suc-LLVY-AMC as substrate. The in vitro eﬀect of A769662 on
both proteasome preparations was analyzed following the correspond-
ing manufacturers instructions. Fluorescence at 535 nm (excitation at
485 nm) in the case of the 26S proteasome reaction, and at 460 nm
(excitation at 360 nm) in the case of the 20S proteasome reaction,
was recorded in a Spectra Max M5 microplate reader (Molecular De-
vices, Sunnyvale, CA).
In-gel peptidase overlay assays with puriﬁed 26S and 20S protea-
somes were carried out using native gel electrophoresis and Suc-
LLVY-AMC as substrate as in [17]. Three micrograms of commercial
puriﬁed 26S and 20S proteasomes (see above) were used in these as-
says. After visualization of the reaction, the gels were stained with
Coomassie blue.2.4. Immunoblot analysis
Cell lysates were prepared as described in [10]. Sixty lg of total
protein from cell lysates were analyzed by SDS–PAGE and Western
blotting using anti-ubiquitin, anti-S1 (19S regulatory particle) or
anti-b2 (20S proteasome) antibodies (Biomol Research Labs; Exeter,
UK).2.5. Flow cytometry and microscopic analysis
Cell viability of MEF cells treated or not with A769662 was per-
formed as follows: cells were harvested by trypsinization and incubated
with 0.5 mg/ml RNase and 50 lg/ml propidium iodine at room temper-
ature in the dark; cell viability was analyzed by ﬂow cytometry using a
FACScanto ﬂow cytometer (Becton Dickinson), using an excitation la-
ser at 488 nm and a propidium iodine ﬂuorescence detection at 600 nm.
To determine the proportion of cells in each phase of the cell cycle,
cells were harvested by trypsinization, collected by centrifugation,
washed in PBS and ﬁxed overnight in 80% ethanol at 20 C. Subse-
quently, these ﬁxed cells were centrifuged to remove the ﬁxative and
incubated for 20 min in the dark at room temperature in PBS contain-
ing 0.5 mg/ml RNase and 50 lg/ml propidium iodine. Flow cytometry
analysis was performed as above. The proportion of cells in G1, S, and
G2 was determined using the MODFIT program.
Cell culture pictures were taken at the indicated times using a camera
(Olympus Camedia C-5060 wide zoom) coupled to an inverted micro-
scope (Zeiss Axiovert 40C) with a 20· objective.2.6. Statistical data analysis
Data are expressed as mean values ± standard error (S.E.). Statisti-
cal signiﬁcance of diﬀerences between the groups was evaluated by a
paired Students t test with two-tailed distribution. The signiﬁcance
has been considered at **P < 0.01 or ***P < 0.001, as indicated.3. Results and discussion
3.1. A769662 inhibits proteasomal activity by an AMPK-
independent mechanism
We have recently described that activation of AMPK, either
by AICAR or by metformin, aﬀects negatively proteasomal
function [10]. To conﬁrm these results we have used a novel
activator of AMPK named A769662 (see Section 1). In agree-
ment with previous results, treatment of wild-type mouse
embryonic ﬁbroblast (MEF) cells with A769662 resulted in
an increase in the phosphorylation of the AMPKa catalytic
subunit at Thr172 residue (data not shown). This new com-
pound was also able to inhibit in vivo the proteasomal func-
tion in MEF cells, with an IC50 of 62 lM (Fig. 1A).
However, the compound was also able to inhibit in vivo the
proteasomal function in AMPKa subunit double knockout
(a1/, a2/) MEFs, with similar IC50 (47 lM; no statisti-
cally signiﬁcant diﬀerences were found respect to wild-type
MEFs), indicating that A769662 was able to inhibit proteaso-
mal function in an AMPK-independent manner (Fig. 1A).
A769662 was not as potent as other already known proteaso-
mal inhibitors such as lactacystin, which has an IC50 in the
nanomolar range [18]; in fact, 10 lM of lactacystin was able
to inhibit almost completely proteasomal function (Fig. 1).
We then conﬁrmed that A769662 was an inhibitor of prote-
asomal function by alternative methods. As it is shown in Fig.
1B, MEF cells treated with 300 lM A769662 for 1 h were able
to accumulate poly-ubiquitinated proteins, an indication of
proteasomal impairment, as in the case of cells treated with
the proteasomal inhibitor lactacystin (10 lM) (similar results
were obtained in double a1a2/ KO MEF cells; not shown).
In addition, we used an alternative assay based on the degra-
dation of a fusion protein of GFP with a short degron (CL1)
fused to the C-terminus (GFPu) [15]. This fusion protein is
unstable and is rapidly degraded by the 26S proteasome under
regular conditions. If the function of the proteasome is im-
paired, then the GFPu protein is accumulated, what leads to
an increase in the amount of GFP-dependent ﬂuorescence.
As shown in Fig. 1C, treatment of HEK-GFPu-1 cells with
lactacystin (10 lM) resulted in an increase in the GFP-depen-
dent ﬂuorescence of the cells, assessed by ﬂow cytometry.
When the cells were treated with A769662, we also observed
an increase in GFP-dependent ﬂuorescence that was dose-
dependent (Fig. 1C).
We also studied the possibility that A769662 could aﬀect
indirectly proteasome function, i.e. by preventing transcription
or translation of proteasomal genes. However, we ruled out
this possibility when we observed similar amounts of two char-
acteristic endogenous subunits of the proteasome, such as the
S1 subunit from the 19S regulatory particle and the b2 subunit
from the 20S proteasome catalytic core, in extracts from cells
treated or not with 300 lM A769662 for diﬀerent periods of
time (Fig. 1D).
All these results indicated that A769662 was an inhibitor of
the proteasomal function and that the mechanism of its inhibi-
tion was AMPK-independent.
3.2. Inhibition of proteasomal activity by A769662 is reversible
In all our experiments we grew the cells in complete medium
(DMEM) and then replaced this medium by a poor medium
(KH) to increase intracellular protein degradation. In order
to determine whether A769662 inhibited the activation of the
Fig. 1. A769662 inhibits proteasomal function by an AMPK-inde-
pendent mechanism. (A) Wild-type (WT) and AMPKa subunit double
knockout (a1/ and a2/; KO) MEFs were cultivated in complete
DMEM medium. Then, they were incubated for 1 h in KH medium
containing lactacystin (10 lM), diﬀerent amounts of A769662 (from 10
to 300 lM) or the corresponding vehicle (DMSO; 0 lM). The in vivo
activity of the proteasome was determined in these cells as described in
Section 2. Results were referred to the activity found in wild-type
MEFs cells growing in KH medium with DMSO. (B) Sixty micro-
grams of total protein from cell lysates from treated MEF cells as
above were analyzed by SDS–PAGE and western blotting using anti-
ubiquitin antibodies; Lact: lactacystin (10 lM); A769662 (300 lM). (C)
HEK-GFPu-1 cells were cultivated in DMEM medium and then
incubated for 1 h in KH medium containing lactacystin (Lact; 10 lM),
A769662 (A; 50 lM or 300 lM) or the corresponding vehicle (DMSO).
Fluorescence was determined as described in Section 2 and referred to
the ﬂuorescence found in KH medium with DMSO. (D) Sixty
micrograms of total protein from cell lysates from MEF cells treated
as above with A769662 (300 lM) or with vehicle (DMSO) for diﬀerent
times, as indicated, were analyzed by SDS–PAGE and western blotting
using anti-S1 (19S regulatory particle) or anti-b2 (20S proteasomes)
antibodies. Bars indicate S.E.
Fig. 2. Inhibition of proteasomal activity by A769662 is reversible. (A)
Wild-type MEF cells were grown in complete DMEM medium and
then incubated for 1 h in KHmedium. Then, the cells were treated with
50 lM A769662 or with DMSO in KH for an extra hour. The in vivo
proteasomal activity was measured as described in Section 2. (B) Wild-
type MEF cells were grown in complete DMEM medium and then
incubated for 1 h in KH medium containing or not 50 lM A769662;
then, the media were removed, replaced by fresh KH medium and the
cells were incubated for an extra hour. The in vivo proteasomal activity
was measured as above. In (A) and (B), results are referred to the
activity measured in the cells incubated for 1 h in KH medium without
A769662; bars indicate S.E. and asterisks indicate diﬀerences which
were found to be statistically signiﬁcant at P < 0.01 (n: 4).
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medium or whether this compound was able to inhibit a pre-
existing proteasomal activity, we subjected MEF cells to a shift
from complete to KH medium for 1 h and then, treated the
cells with A769662 or with vehicle alone (DMSO). We ob-
served that A769662 was able to reduce the activity of
pre-existing proteasomal activity (Fig. 2A), suggesting a direct
eﬀect of the compound on the proteasome. Additionally, we
checked whether the inhibition was reversible. With this aim,
we treated MEF cells with A769662 for 1 h and then, we re-moved the culture medium and replaced it with fresh KH med-
ium for an extra hour. As observed in Fig. 2B, a clear increase
in the activity of the proteasome was observed upon removal
of A769662, indicating a reversible mechanism of inhibition.
3.3. A769662 aﬀects in vitro the activity of puriﬁed 26S but not
the activity of 20S proteasomes
The 26S proteasome is a high molecular weight proteolytic
complex consisting of the 20S core, where proteins are de-
graded, plus one or two 19S regulatory particles, composed
of six ATPases and other components necessary for binding,
unfolding and translocation of the protein substrates into the
20S core for hydrolysis (see Section 1). In order to determine
whether A769662 was able to inhibit in vitro the activity of
either the 26S or the 20S proteasomes, we used commercial
preparations of both complexes. As shown in Fig. 3A, the
activity of the 26S preparation was inhibited by epoxomicin
(0.5 lM), a known proteasomal inhibitor [18]. Similarly,
A769662 was also able to inhibit the activity of the 26S
Fig. 3. A769662 aﬀects the in vitro activity of puriﬁed 26S protea-
somes but not the in vitro activity of puriﬁed 20S proteasomes.
Commercial puriﬁed preparations of the 26S proteasome (A) and the
20S proteasome (B) were incubated or not with 0.5 lM epoxomicin
(Epox) or the indicated concentrations of A769662. The activity of the
mixtures was assayed as described in Section 2. Blank: sample
containing no 26S proteasome; in (B), the activity was referred to
the proteasome activity found in the control. Bars indicate S.E. and
asterisks indicate diﬀerences which were found to be statistically
signiﬁcant at P < 0.001 (n: 4). (C) In-gel peptidase overlay assays of
proteasomes were carried out using Suc-LLVY-AMC as substrate (see
Section 2). Three micrograms of commercial puriﬁed 26S proteasomes
were treated with 100 lM A769662 or vehicle (DMSO) for 30 min at
37 C. Three lg of commercial puriﬁed 20S proteasomes were included
as control (left panel). After visualization of the reaction, the gel was
stained with Coomassie blue (right panel).
Fig. 4. A769662 has toxic eﬀects on MEF cells. (A) Cultured MEF
cells from wild-type and double a1/ a2/ KO mice were
incubated at the indicated times in KH medium containing 300 lM
A769662 or the corresponding vehicle (DMSO). (B) Cell viability of
wild-type MEF cells was determined after 24 h of incubation in KH
medium containing DMSO or 300 lM A769662, as described in
Section 2. (C) The percentage of wild-type MEF cells in each phase of
the cell cycle in cultures incubated in the presence of DMSO (white
bars) or in the presence of 300 lM A769662 (grey bars), was
determined at the indicated times, as described in Section 2. Error
bars indicate S.E.
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without 26S proteasomes (blank), even at low concentrations
of the compound (10 lM)], conﬁrming the in vivo inhibition
of proteasomal function described above. However, we were
not able to detect any inhibition of the activity of the 20S pro-
teasome preparation when we used A769662, at any of the
tested concentrations (from 5 to 100 lM) (Fig. 3B). This result
could indicate that A769662 does not aﬀect the proteolytic
activity present in the 20S proteasome core. Additionally,
we observed that treatment of the 26S proteasomes with
A769662 did not disrupt the association of the 19S regulatoryparticle with the 20S proteasome (Fig. 3C). Therefore, we
suggest that A769662 inhibits 26S proteasomes by aﬀecting
the function of the 19S regulatory particle, preventing in this
way the entry of the poly-ubiquitinated substrates into the
20S proteolytic chamber.
3.4. A769662 has toxic eﬀects on MEF cells
It has been described that inhibition of the proteasome func-
tion results in cell cycle arrest and apoptosis, probably because
of the accumulation of pro-apoptotic proteins and the down-
regulation of anti-apoptotic factors [8,19]. In order to deter-
mine whether A769662 promoted similar eﬀects, we treated
MEF cells with A769662 and determined its eﬀects on cell cycle
and cell viability. Microscopic analysis of cell cultures indi-
cated that after 12 h of treatment, there was an increase in
the amount of round cells that were not attached to the culture
plate surface. The amount of unattached cells increased dra-
matically after 24 h of treatment (Fig. 4A). Similar results were
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ing that the eﬀect was not due to AMPK activation. Cells were
assessed for viability by ﬂow cytometry and the results indi-
cated a huge increase in the amount of non-viable cells after
24 h of treatment (24.0% of non-viable cells in the samples
treated with A769662 versus 6.3% in cells treated with vehicle
alone; Fig. 4B). Similar results were obtained in double a1a2
/ KO MEF cells (not shown). These results are in contrast
to those previously reported that indicated that A769662
showed no measurable cytotoxicity in rat hepatocytes [11].
Probably the diﬀerent cell type may account for this diﬀerence,
since several studies have demonstrated that proliferating cell
lines are usually more sensitive to proteasome inhibitors than
non-proliferating ones [20,21]. Flow cytometry analysis of
MEF cells indicated that whereas in samples treated with vehi-
cle alone (DMSO) the proportion of cells in G1 increased after
24 h (with the corresponding decrease of cells in G2), samples
treated with A769662 did not show any signiﬁcant variation in
the amount of cells in G1 and G2 after 24 h. These results are
consistent with a cell cycle arrest caused by the inhibition of
the proteasome, as the proteasome is essential for the progres-
sion through many steps in the cell cycle [18,22].
In conclusion, we have demonstrated that A769662 is an
inhibitor of proteasomal function that acts by an AMPK-inde-
pendent mechanism. We have also observed toxic eﬀects of this
compound on MEF cells, probably as a consequence of pro-
teasome inhibition. To our knowledge, this is the ﬁrst time that
side eﬀects of this compound are described and they should be
taken into account when this compound is used as an alterna-
tive activator of AMPK. On the other hand, inhibition of pro-
teasomal activity by A769662 does not involve inhibition of
the proteolytic activity of the 20S proteasome, in contrast to
most proteasomal inhibitors. Thus, the mechanism of action
of A769662 opens a new way in the development of novel
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